BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: McMahon JH, Lau JSY, Coldham A, Roney J, Hagenauer M, Price S, Bryant M, Garlick J, Paterson A, Lee SJ, O'Bryan J, Hearps A, Tachedjian G, Pinskier H, Phillips C, Garrow S, Pinskier N, Melvin R, Blakeway L, Wisniewski JA, Byers S, Badoordeen GZ, Pereira S, Pragastis K, Trubiano JA, Chua KYL, Kainer M, Molton JS, Gardiner BJ, Pierce AB, Cheng A, Rogers BA, Peleg AY. Favipiravir in early symptomatic COVID-19, a randomised placebo-controlled trial. EClinicalMedicine 2022;54:101703. [PMID: 36284645 DOI: 10.1016/j.eclinm.2022.101703] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Batool S, Vuthaluru K, Hassan A, Bseiso O, Tehseen Z, Pizzorno G, Rodriguez Reyes Y, Saleem F. Efficacy and Safety of Favipiravir in Treating COVID-19 Patients: A Meta-Analysis of Randomized Control Trials. Cureus 2023. [DOI: 10.7759/cureus.33676] [Reference Citation Analysis]
2 Siniavin A, Russu L, Vasina D, Shidlovskaya E, Kuznetsova N, Guschin V, Gintsburg A. Efficacy of favipiravir and molnupiravir against novel SARS-CoV-2 variants in vitro and in vivo. BRSMU 2022. [DOI: 10.24075/brsmu.2022.071] [Reference Citation Analysis]
3 Marumo A, Okabe H, Sugihara H, Aoyama J, Kato Y, Arai K, Shibata Y, Fuse E, Nomura M, Kohama K. Clinical Characteristics and Risk Prediction Score in Patients With Mild-to-Moderate Coronavirus Disease 2019 in Japan. Cureus 2022;14:e31210. [PMID: 36505104 DOI: 10.7759/cureus.31210] [Reference Citation Analysis]